medigraphic.com

2014, Number 2

<< Back Next >>

Cir Cir 2014; 82 (2)

Bilateral ovarian Burkitt’s lymphoma. A case presentation

Briseño-Hernández AA, Quezada-López DR, Castañeda-Chávez A, Macías-Amezcua MD, Pintor-Belmontes JC

Language: Spanish
References: 24
Page: 212-218
PDF size: 382.17 Kb.


ABSTRACT

Background: Burkitt lymphoma, is described as an aggressive form of non-Hodgkin lymphoma of B cells which occurs most often in children and young adults, ovarian lymphoma can appear as a primary lesion or more commonly referred to as a metastasis. Primary ovarian lesions are rare manifestations corresponding to 0.5% of non-Hodgkin lymphoma and 1.5% of ovarian tumors.
Clinic case: 31 years old female with general weakness, march incapacity, dyspnea, hyporexia, fever, diaphoresis, weight loss of 20 kg, flat abs with abdominal pain; Ca125 610 U/ml. Abdominal computed tomography shows a solid aspect tumor which affects the right pelvic cavity. Bilateral ovarian tumors were removed. Microscopically, both lesions show a “starry sky” pattern composed by a monotonous infiltration of lymphocytes mixed with large and clear macrophages, several atypical mitoses, and necrosis and hemorrhage areas. Immunohistochemistry was positive for CD10, CD20, and negative for CD3 and high Ki67 proliferation index. Bilateral ovarian Burkitt’s lymphoma was diagnosed.
Conclusion: Bilateral ovarian Burkitt´s lymphoma is a rare entity, with a variability of presentations, the abdominal pain and abdominal tumors are the most frequent. The patient’s prognosis at short term is poor, therefore it’s necessary to know this entity and make an early diagnosis.


REFERENCES

  1. Bonet-Fonseca I, Díaz-Anaya A. Francis T, Fajardo-Tornés YL. Linfoma de ovario. Rev Cub Obste Ginecol 2012;38:424- 430.

  2. Hatami M, Whitney K, Goldberg GL. Primary bilateral ovarian and uterine Burkitt’s lymphoma following chemotherapy for breast cancer. Arch Gynecol Obstet 2010;281:697-702.

  3. Taylor JS, Frey MK, Fatemi D, Robinson S. Burkitt’s lymphoma presenting as ovarian torsion. Am J Obstet Gynecol 2012;207:e4-e6.

  4. Tumwine LK, Agostinelli C, Campidelli C, Othieno E, Wabinga H, Righi S, et al. Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda. BMC Clin Pathol 2009;16:1-7.

  5. Onimoe GI, Kahwash S, Termuhlen A, Gross TG, Varga E, Rose MJ. Bilateral Burkitt Lymphoma of the Ovaries: A Report of a Case in a Child with Williams Syndrome. Case Report Med 2011;2011:1-4.

  6. Chuang SS, Ye H, Du MQ, Lu CL, Dogan A, Hsieh PP, et al. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Pathol 2007;128:558-564.

  7. Cabanillas F. Non-Hodgkin’s Lymphoma: The Old and the New. Clin Lymphoma Myeloma Leuk 2011;11(Suppl 1):S87-S90.

  8. Mori HT. Ovarian metastases of lymphomas and other hematological malignancies. CME J Gynecol Oncol 2004;9:195-197.

  9. Vang R, Medeiros LJ, Warnke RA, Higgins JP, Deavers MT. Ovarian Non-Hodgkin’s Lymphoma: A Clinicopathologic Study of Eight Primary Cases. Mod Pathol 2001;14:1093- 1099.

  10. Ng SP, Leong CF, Nurismah MI, Shahila T, Jamil MA. Primary Burkitt Lymphoma of the Ovary. Med J Malaysia 2006;61:363-365.

  11. Chishima F, Hayakawa S, Ohta Y, Sugita K, Yamazaki T, Sugitani M, et al. Ovarian Burkitt’s lymphoma diagnosed by a combination of clinical features, morphology, immunophenotype, and molecular findings and successfully managed with surgery and chemotherapy. Int J Gynecol Cancer 2006;16(Suppl 1):337-343.

  12. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hemrlink HK, Vardiman J, et al. World Health Organization Classification of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.

  13. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO Staging Classifications and Clinical Practice Guidelines for Gynaecologic Cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:207-312.

  14. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636.

  15. Fox H, Langley FA, Govan ADT, Hill AS, Bennett MH. Malignant lymphoma presenting as an ovarian tumor: a clinicopathological analysis of 34 cases. Br J Obstet Gynaecol 1988;95:386-390.

  16. Ferrozzi F, Catanese C, Uccelli M, Bassi P. Ovarian lymphoma. Findings with ultrasonography, computerized tomography and magnetic resonance. Radio Med 1998;95:493-497.

  17. Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL. Comparative Immunohistochemical Analysis of Pediatric Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma. Am J Clin Pathol 2004;121:384-392.

  18. Huang YH, Wu QL, Zong YS, Feng YF, Liang JZ, Hou JH, et al. Clinicopathologic features and Epstein-Barr virus infection status of Burkitt’s lymphoma in Guangzhou district. Chin J Can 2009;28:805-812.

  19. Guía de Práctica Clínica, Linfomas No Hodgkin en el Adulto. México: Secretaria de Salud 2009 (consultado 17 Abr 2013). Disponible en http://www.cenetec.salud.gob.mx/descargas/ gpc/CatalogoMaestro/174_GPC_LINFOMA_NO_HODGKIN/ Imss_174ER.pdf.

  20. Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of Treatment With Hyper-CAVD, a Dose- Intensive Regimen, in Adult Acute Lymphocytic Leukemia. J Clin Oncol 2000;18:547-561.

  21. Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, García-Manero G, et al. Chemoimmunotherpy whit hyper- CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580.

  22. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle- Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. J Clin Oncol 2005;23:7013-7023.

  23. Weingertner AS, Hamid D, Roedlich MN, Baldauf JJ. Non- Hodgkin malignant lymphoma revealed by an ovarian tumor: case report and review of the literature. Gynecol Oncol 2004;95:750-754.

  24. Yamada T, Iwao N, Kasamatsu H, Mori H. A case of malignant lymphoma of the ovary manifesting like an advanced ovarian cancer. Gynecol Oncol 2003;90:215-219.




2020     |     www.medigraphic.com